226 Tamminga CA, Gotts MD, Thaker GK, et al. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 1986; 43:398-402.
227 Tamminga CA, Cascella NG, Lahti RA, et al. Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect 1992; 88:165-175.
228 Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999; 20:612-627.
229 Saha A, Ali MW, Ingenito GG, Wilber R, et al. Safety and tolerability of aripiprazole at doses higher than 30 mg. Int J Neuropsychopharmacology 2002; 5:S185.
230 Stock E, Soha AR, Brunell R, Achibald DG. Meta-analysis of the cardiac safety with aripiprazole. Int J Neuropsychopharmacology 2002; 5:186.
231 Lieberman J, Carson WH, Saha AR, et al. Meta-Analysis of the efficacy of aripiprazole in schizophrenia. Int J Neuropsychopharmacology 2002; 5:186.
232 Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35:51-68.
233 Chakos M, Lieberman J, Hoffman E, et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158:518-526.
234Meltzer HY, Alphs L, Green AI, et al. Clozapine Treatment for suicidality in schizophrenia. International Suicide Prevention Trial (InterSePT) (Reprinted). Arch Gen Psychiatry 2003; 60:82-91.
235Buchanan RW, Kreyenbuhl J, Zito JM, Lehman A. Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia. Am J Psychiatry 2002; 159:1035-1043.
236 Casey DE, Daniel DG, Wassef AA, et al. Effect of Divalproex combined with olanzapine and risperidone in patients with an acute exacerbation in schizophrenia. Neuropsychopharmacology 2003; 28:182-192.
237Javitt DC, Silipo G, Cienfuegos A, et al. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol 2001; 4:385-391.